MannKind (MNKD) Stock Continues to Gain Following Friday's Rally

NEW YORK (TheStreet) -- Shares of MannKind (MNKD) are gaining, up 5.01% to $4.19 in mid-morning trading Monday, continuing its rally from the prior session on Friday.

Analysts at Jefferies issued a note Friday morning saying they see "good interest" for use of MannKind's Afrezza drug.

Afrezza, the company's signature drug, is an inhalable product to treat diabetes.

The firm reiterated its "buy" rating with a price target of $9 following its recent Afrezza survey.

Jefferies surveyed 56 endocrinologists and primary care physicians about their expected use of Afrezza for diabetes.

The firm said in a note, In screening physicians, we found that 35% did not know about Afrezza. Those that did, however, expected to use Afrezza more frequently than we had expected, especially among type 1 diabetics.

MannKind is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes. The company is based in Valencia, Calif.

MNKD ChartMNKD data by YCharts

More from Markets

Treasury Secretary Mnuchin: 'Take the Over' on U.S. GDP Topping 3% This Year

Treasury Secretary Mnuchin: 'Take the Over' on U.S. GDP Topping 3% This Year

Video: Why the Stock Market Is Discounting China Trade Fears for Now

Video: Why the Stock Market Is Discounting China Trade Fears for Now

Global Stocks Rally as US-China Trade War Thaws; Dow Could Test 25,000

Global Stocks Rally as US-China Trade War Thaws; Dow Could Test 25,000

GE Confirms $11.1 Billion Transportation Merger With Wabtec

GE Confirms $11.1 Billion Transportation Merger With Wabtec

China Trade Truce, General Electric and Tesla - 5 Things You Must Know

China Trade Truce, General Electric and Tesla - 5 Things You Must Know